| Species |
Human |
| Protein Construction |
CD96/TACTILE (Val22-Met503)
Accession # P40200-2 |
His |
Avi |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized AntiCD96 Antibody, hFc Tag at 1μg/ml (100μl/well) on the plate can bind CD96/TACTILE[Biotin], His & Avi, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
59.1 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 115-140 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development. |
| Synonyms |
CD96 molecule; CD96; DKFZp667E2122; TACTILE |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
